Soticlestat, a CH24H inhibitor in phase 3 development for the treatment of seizures for patients with Dravet and Lennox–Gastaut syndrome, exhibited dose-dependent displacement of [18F]T-008 in the brain. Explore the potential of [18F]T-008 as a reliable radiotracer for CH24H analysis in advancing neuroscience research and drug development. #imagingCRO #scientificpublications https://hubs.ly/Q02d4tkb0
Invicro’s Post
More Relevant Posts
-
We are pleased to share that Dewpoint has contributed an insightful article to the latest eReport on neuroscience. The article, authored by our very own Diana Mitrea, 'Leveraging the power of molecular communities' explores the groundbreaking potential of targeting biomolecular condensates for therapeutic development. Diana discusses how our AI-powered platform is used to identify novel condensate targets, validate hypotheses, and discover and optimize c-mods (condensate-modulating drugs). This approach shows promising results in addressing complex diseases such as ALS by targeting aberrant condensates and restoring cellular function. Dive into the details of our innovative research and its implications for future treatments here https://bit.ly/4bwh48G
The global prevalence of dementia is approximately 24 million, and is predicted to double every 20 years until at least 2040. Currently, no medications can cure this, though 2024 has proved to be a poignant year of developments in neuroscience, especially considering the challenges faced in previous decades. This guide, sponsored by ApconiX, showcases the potential within drug discovery. While putting this report together, it was a pleasure to hear insight from ApconiX’s Director and Co-founder, Professor Ruth Roberts, and Scientific Lead, Kimberly Rockley. In addition, a scientific article by Dewpoint Therapeutics' Associate Director for Scientific Communications Diana Mitrea on developing therapeutics targeting biomolecular condensates. Register and download this FREE e-report now. https://hubs.li/Q02DS40t0
-
Exploring the impact of cannabinoids on brain cell activity
Exploring the Impact of Cannabinoids on Brain Cell Activity: Research Insights
endocaresupply.com
-
CEO of Axol Bioscience, enabling “Better Human Disease Models” with iPSC technology in neurodegenerative disease
iPSC and Cardiac Disease Scientists Q.) How do you take adolescent looking cardiomyocytes to adult looking cardiomyocytes? A.) Collaborate and invest time, energy and focus on the MATURATION MEDIA See the post attached to learn more about “Evaluation of a new media designed to drive improved maturity of iPSC-derived cardiomyocytes for cardiac disease, cardiotoxicity and drug screening". #MEA #cellculture #ISSCR #cardiacdisease #MPS #organoids #organonchip #biotech #pharma
Missed The Physiology Society Conference last week? We made our poster available for download! Our Senior Scientific Support Manager Dr Steven Broadbent presented a poster titled "Evaluation of a new media designed to drive improved maturity of iPSC-derived cardiomyocytes for cardiac disease, cardiotoxicity and drug screening". With market-leading iPSC products and services for neuroscience and cardiovascular research and toxicity screening, Axol Bioscience has become the first choice for in vitro research. Get in touch with us at operations@axolbio.com for a discussion about your research needs. Click here to download the poster: https://hubs.la/Q02FyrvP0 #iPSCs #PhySoc #StemCells #biopharma
-
-
In a recent investor webinar, our Executive Director, Dr. Thomas Duthy, shared exciting updates on our progress in developing a treatment for #RettSyndrome. Dr Duthy highlighted the success of our Phase I/II clinical trial (NTIRTT1) using NTI164, a broad-spectrum cannabinoid drug therapy. The trial demonstrated significant clinical benefits and safety in girls with Rett Syndrome. Dr Duthy expressed his pride in $NTI's achievements, stating, "The company has delivered in spades. We have had three clinical trials in PANDAS, PANS, Autism and now Retts Syndrome. All basically deliver results and we're very proud of that." #Neurotech #NTI #RettSyndrome #ClinicalTrial #Neuroscience #biotech #smallcaps #smallcapstocks #biotechnology #investors #PANDAS #PANS #autism
-
At EphyX Neuroscience, we take pride in offering unparalleled quality services that combine scientific excellence with exceptional human interaction. Here's what sets us apart: ➡ Trustworthy results: Our team of highly skilled PhD experimenters utilizes cutting-edge techniques to deliver top-quality, reliable results. ➡ Fast turnaround: With state-of-the-art equipment and expertise, we ensure quick and efficient project completion. ➡ Unmatched flexibility: We understand that research is dynamic, and we offer the flexibility to make changes on the go without delay. Our adaptable approach allows us to modify projects based on incoming results, and even stop ongoing projects if results appear irrelevant. ➡ Dedicated support: Our clients benefit from a dedicated contact who is available anytime for discussion or advice. Choose EphyX Neuroscience for a seamless and successful research experience. ➡ contact@ephyx-neuroscience.com #Electrophysiology #DrugDiscovery #CNS #DrugDevelopment #PreclinicalResearch #MOA #Pharma #CNSResearch #ContractResearch
-
-
At Enveric Biosciences, Inc., we have synthesized hundreds of proprietary molecules utilizing our artificial intelligence platform, PsyAI™. WIth our platform, we are optimizing drug discovery, narrowing down the potential compounds to select neuroplastogens candidates with potential for various undertreated neuropsychiatric disorders. To learn more about Enveric's artificial intelligence platform, PsyAI™, visit Enveric.com. #ENVB #MentalHealth #Biotechnology #Neuroplasticity
-
-
The key to drug discovery and disease modeling in neuroscience: Astrocytes. They play an essential role in neurodegenerative disease progression and are thus a key player in unlocking the secrets of these conditions. We can provide off-the-shelf Ncyte Astroyctes or manufacture astrocytes from the iPSC that fit your project best to model relevant disease phenotypes and support your drug discovery campaigns. Are you looking to use human iPSC-derived astrocytes for your drug discovery projects? Read more about them and contact an expert here: https://lnkd.in/exBxT7Qy
-
-
🔬Citation Break!📖 This citation studies the relationship between endogenous Alpha-Synuclein expression and neuronal cell death. Our Alpha-Synuclein (cat# S-1001) was used to generate fibrils for further experimentation. rPeptide offers an array of Synuclein monomers, as well as preformed Alpha-Synuclein Fibrils (cat# ASF-1001) for those wishing to avoid the time consuming and costly fibrillization processes. Paper: https://t.ly/Q4TDv Alpha-Synuclein: https://t.ly/aLInt #Research #Development #Experiment #Alpha #Synuclein
Brain Pathology | ISN Neuropathology Journal | Wiley Online Library
onlinelibrary.wiley.com
-
Impact Factor: 4.8 | Volume 22, Issues 14, 2024 🔹 Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed 🔹 Ranking: 69th in Neurosciences | 40th in Pharmacology & Pharmacy Aims & Scope: Current Neuropharmacology publishes comprehensive and mini-reviews on molecular, cellular, and systems/behavioral neuropharmacology and neuroscience. We also consider novel position papers, research articles, and clinical trials. Guest-edited issues span all areas of neuropharmacology. 🔬 Stay updated with the latest advancements in neuropharmacology and neuroscience. Explore innovative research and expert reviews in our latest issue! 🔗https://bit.ly/3X34vh4 Learn more and submit your work today!
-
-
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies - FENS Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease Data demonstrates improvement in cognitive function in GBA1 hashtag #Parkinson’s disease model in addition to reversal of motor function deficits https://lnkd.in/gnzP6jg2
-
